Supernus Pharmaceuticals (SUPN) Notes Payables (2022 - 2023)
Supernus Pharmaceuticals (SUPN) posted quarterly Notes Payables of $402.5 million for Q1 2023, little changed on a QoQ basis from $402.0 million in Q4 2022.
Supernus Pharmaceuticals (SUPN) Notes Payables (2022 - 2023) Analysis & Trends
Supernus Pharmaceuticals has reported Notes Payables for 2 years, with the latest figure at $402.5 million in Q1 2023.
- Notes Payables for Q1 2023 came in at $402.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2023 was $402.5 million (changed N/A YoY), and the FY2022 annual result was $402.0 million, changed N/A from the prior year.
- Notes Payables steadied at $402.5 million in Q1 2023, from $402.0 million in the prior quarter.
- Over five years, Notes Payables peaked at $402.5 million in Q1 2023 and troughed at $402.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 402.50 Mn |
| Dec 31, 2022 | 401.97 Mn |